AnPac Bio-Medical Science Co., Ltd.
ANPC · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.04 | 0.16 | -0.00 |
| FCF Yield | -91.79% | -71.78% | -15.88% | -6.70% |
| EV / EBITDA | -0.72 | -1.16 | -5.07 | -8.63 |
| Quality | ||||
| ROIC | -2,066.24% | -273.89% | -637.37% | -350.61% |
| Gross Margin | 69.21% | 68.13% | 62.81% | 44.24% |
| Cash Conversion Ratio | 0.53 | 0.60 | 0.73 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.26% | 18.37% | 26.01% | 24.02% |
| Free Cash Flow Growth | 25.14% | -23.14% | -18.74% | -52.27% |
| Safety | ||||
| Net Debt / EBITDA | -0.10 | -0.22 | -0.07 | -0.35 |
| Interest Coverage | -225.57 | -24.91 | -81.48 | -34.14 |
| Efficiency | ||||
| Inventory Turnover | 17.66 | 11.70 | 24.45 | 19.32 |
| Cash Conversion Cycle | -18.91 | -30.05 | 74.55 | -27.49 |